Clinical Trial Update: Safety of New Formulation of Glatiramer Acetate [Phase 3]

View source ↗

Summary

A Phase 3 trial assessing the safety of a new formulation of glatiramer acetate in relapsing-remitting multiple sclerosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Glatiramer acetate (Copaxone) (glatiramer acetate)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2011-06-09